Jessiman-Perreault, Geneviève
Law, Jessica
Adhikari, Kamala
Machado, Amanda Alberga
Moysey, Barbara
Xu, Linan
Yang, Huiming
Scott, Lisa K. Allen
Teare, Gary
Li, Alvin
Article History
Received: 28 March 2023
Accepted: 16 December 2023
First Online: 21 December 2023
Declarations
:
: This study analyze secondary data. This study has received research ethics approval from the Health Research Ethics Board of Alberta (HREBA.CC-20-0425). The Health Research Ethics Board of Alberta Cancer Committee waived the informed consent. All methods were carried out in accordance with relevant guidelines and regulations. This Committee is constituted and operates in accordance with the Alberta Health Information Act (HIA), the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2), Good Clinical Practice (GCP) Guidelines of the International Conference on Harmonization (ICH), Health Canada’s Food and Drug Regulations (FDR), Part C, Division 5 and is registered with the U.S. Department of Health and Human Services (HHS), Office for Human Research Protections (OHRP), IRB # 00009687, and the Declaration of Helsinki. Informed consent from participants was not required because we used health information routinely collected in Alberta and held in health administrative databases from which only unique encoded identifiers were analyzed by the core study team. No identifying information was retained by the study team.
: Not applicable.
: The authors declare no competing interests.